EP1640368A3 - Composés urées cycliques et leur procédé de préparation - Google Patents

Composés urées cycliques et leur procédé de préparation Download PDF

Info

Publication number
EP1640368A3
EP1640368A3 EP05015015A EP05015015A EP1640368A3 EP 1640368 A3 EP1640368 A3 EP 1640368A3 EP 05015015 A EP05015015 A EP 05015015A EP 05015015 A EP05015015 A EP 05015015A EP 1640368 A3 EP1640368 A3 EP 1640368A3
Authority
EP
European Patent Office
Prior art keywords
compounds
carbamic acid
new
function
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05015015A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1640368A2 (fr
Inventor
Gilles Guichard
Serge Plaue
Vincent Semetey
Arnaud-Pierre Schaffner
Jean-Paul Briand
Marc Rodriguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
ImmuPharma France SA
Original Assignee
Centre National de la Recherche Scientifique
ImmuPharma France SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, ImmuPharma France SA filed Critical Centre National de la Recherche Scientifique
Publication of EP1640368A2 publication Critical patent/EP1640368A2/fr
Publication of EP1640368A3 publication Critical patent/EP1640368A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/04—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/04—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D259/00—Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Fats And Perfumes (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP05015015A 2000-06-13 2001-06-13 Composés urées cycliques et leur procédé de préparation Withdrawn EP1640368A3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0007507A FR2810039B1 (fr) 2000-06-13 2000-06-13 Composes urees cycliques et leur procede de preparation
PCT/FR2001/001837 WO2001096318A1 (fr) 2000-06-13 2001-06-13 Composes urees cycliques et leur procede de preparation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP01945420A Division EP1289968B1 (fr) 2000-06-13 2001-06-13 Composes urees cycliques et leur procede de preparation

Publications (2)

Publication Number Publication Date
EP1640368A2 EP1640368A2 (fr) 2006-03-29
EP1640368A3 true EP1640368A3 (fr) 2007-03-28

Family

ID=8851208

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05015015A Withdrawn EP1640368A3 (fr) 2000-06-13 2001-06-13 Composés urées cycliques et leur procédé de préparation
EP01945420A Expired - Lifetime EP1289968B1 (fr) 2000-06-13 2001-06-13 Composes urees cycliques et leur procede de preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP01945420A Expired - Lifetime EP1289968B1 (fr) 2000-06-13 2001-06-13 Composes urees cycliques et leur procede de preparation

Country Status (13)

Country Link
US (1) US7186828B2 (enExample)
EP (2) EP1640368A3 (enExample)
JP (1) JP5054877B2 (enExample)
KR (1) KR20030031001A (enExample)
AT (1) ATE386728T1 (enExample)
AU (2) AU6764501A (enExample)
CA (2) CA2412782C (enExample)
DE (1) DE60132891T2 (enExample)
DK (1) DK1289968T3 (enExample)
ES (1) ES2301554T3 (enExample)
FR (1) FR2810039B1 (enExample)
IL (1) IL153408A0 (enExample)
WO (1) WO2001096318A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006016168D1 (de) * 2005-12-29 2010-09-23 Immupharma France Sa 1,3,5-triazepin-dionen zur Behandlung von Malaria
AU2006331355B2 (en) * 2005-12-29 2011-09-29 Immupharma France Sa Compositions and methods for the inhibition of phospholipase A2
US7777030B2 (en) 2005-12-29 2010-08-17 Centre National de la Recherge Scientifique (CNRS) Compositions and methods for the treatment and prevention of disease
AU2006331357B2 (en) * 2005-12-29 2012-05-17 Immupharma France Sa Compositions and methods for synthesizing novel heterocyclic therapeutics
JP2009522236A (ja) * 2005-12-29 2009-06-11 イミュファルマ・フランス・エスアー マラリアまたはエイズの処置のためのアザ複素環化合物
US8563115B2 (en) 2008-08-12 2013-10-22 Xerox Corporation Protective coatings for solid inkjet applications
US8191992B2 (en) * 2008-12-15 2012-06-05 Xerox Corporation Protective coatings for solid inkjet applications
EP2548869A1 (en) * 2011-07-20 2013-01-23 Cytec Technology Corp. Process for the Synthesis of N-substituted Cyclic Alkylene Ureas
CN102911130B (zh) * 2011-08-03 2015-05-20 北京师范大学 一种一锅法合成脲四元环化合物的方法、合成的脲四元环化合物
EP3640263A1 (en) 2013-08-21 2020-04-22 UREKA Sarl Peptide-oligourea chimeric compounds and methods of their use
WO2016207726A1 (en) 2015-06-22 2016-12-29 Ureka Sarl Bioinspired catalysis using oligourea helical foldamers
WO2017037142A1 (en) 2015-08-31 2017-03-09 Centre National De La Recherche Scientifique (Cnrs) Foldamer helix bundle-based molecular encapsulation
AU2017252015A1 (en) 2016-04-19 2018-11-08 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
US12434075B2 (en) * 2021-05-11 2025-10-07 Celestial Oncology Inc. Coupled robotic radiation therapy system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029329A1 (en) * 1995-03-17 1996-09-26 The Du Pont Merck Pharmaceutical Company Cyclic urea hiv protease inhibitors
WO1998020009A1 (en) * 1996-11-08 1998-05-14 Dupont Pharmaceuticals Company (4r,5s,6s,7r)-hexahydro-1- [5-(3-aminoinazole)methyl] -3-butyl-5,6-dihydroxy-4,7-bis [phaenylmethyl] -2h-1,3-diazepin-2-one, its preparation and its use as hiv protease inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2847760A1 (de) * 1978-11-03 1980-05-14 Hoechst Ag Verfahren zur herstellung von 1,3,5-triaza-2,4,6-triketo-cycloheptan- 3,5-di-essigsaeureestern
US4918186A (en) * 1986-05-06 1990-04-17 Mitsui Toatsu Chemicals, Inc. Process for producing cyclic ureas
KR100268694B1 (ko) * 1991-10-11 2000-10-16 미리암 디. 메코너헤이, 블레어큐. 퍼거슨 레트로바이러스 프로테아제 억제제로 유용한 시클릭 우레아 및 유사체
US5610294A (en) * 1991-10-11 1997-03-11 The Du Pont Merck Pharmaceutical Company Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
US5637780A (en) 1993-03-30 1997-06-10 The Dupont Merck Pharmaceutical Company Method for preparing alkylating agents and their use for alkylating cyclic ureas
US5508400A (en) * 1994-04-20 1996-04-16 The Du Pont Merck Pharmaceutical Company Preparation of cyclic urea compounds
US5532356A (en) * 1995-06-06 1996-07-02 The Dupont Merck Pharmaceutical Company Method for preparing N,N'-disubstituted cyclic ureas
US5532357A (en) * 1995-06-07 1996-07-02 The Dupont Merck Pharmaceutical Company Method for preparing N-monosubstituted and N,N'-disubstituted unsymmetrical cyclic ureas
WO1997008150A1 (en) 1995-08-22 1997-03-06 The Du Pont Merck Pharmaceutical Company Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029329A1 (en) * 1995-03-17 1996-09-26 The Du Pont Merck Pharmaceutical Company Cyclic urea hiv protease inhibitors
WO1998020009A1 (en) * 1996-11-08 1998-05-14 Dupont Pharmaceuticals Company (4r,5s,6s,7r)-hexahydro-1- [5-(3-aminoinazole)methyl] -3-butyl-5,6-dihydroxy-4,7-bis [phaenylmethyl] -2h-1,3-diazepin-2-one, its preparation and its use as hiv protease inhibitor

Also Published As

Publication number Publication date
DE60132891D1 (de) 2008-04-03
US20040044199A1 (en) 2004-03-04
KR20030031001A (ko) 2003-04-18
WO2001096318A1 (fr) 2001-12-20
JP2004503546A (ja) 2004-02-05
AU2001267645B2 (en) 2006-07-27
ES2301554T3 (es) 2008-07-01
CA2412782C (en) 2012-08-07
DE60132891T2 (de) 2009-03-19
JP5054877B2 (ja) 2012-10-24
EP1289968A1 (fr) 2003-03-12
CA2778314C (en) 2017-01-03
FR2810039B1 (fr) 2007-05-25
FR2810039A1 (fr) 2001-12-14
AU6764501A (en) 2001-12-24
CA2778314A1 (en) 2001-12-20
IL153408A0 (en) 2003-07-06
WO2001096318A8 (fr) 2003-05-01
EP1640368A2 (fr) 2006-03-29
ATE386728T1 (de) 2008-03-15
CA2412782A1 (en) 2001-12-20
EP1289968B1 (fr) 2008-02-20
US7186828B2 (en) 2007-03-06
DK1289968T3 (da) 2008-06-23

Similar Documents

Publication Publication Date Title
AU6764501A (en) Cyclic urea compounds and preparation thereof
WO2002070486A1 (en) Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity
AU6180894A (en) Cyclic ureas and analogues useful as retroviral protease inhibitiors
EP1595890A3 (en) Synthetic peptide inhibitors of HIV transmission
WO2000002987A3 (en) Amine reaction compounds comprising one or more active ingredient
HUP9902818A3 (en) Compounds with anti-inflammatory and immunosuppressive activities
AU7447194A (en) Higher purity imidazoline based amphoacetate surfactants and processes for the preparation thereof
ATE245435T1 (de) Totalsynthese des amino hip analogen von didemnin a
CA2237189A1 (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists
CA2240964A1 (en) Piperidone tachykinin antagonists
DK0640081T3 (da) Substituerede phenylcarbarmater og phenylurinstoffer, deres fremstilling og deres anvendelse som 5-HT4-antagonister
DE69015451D1 (de) Enzym-inhibierende Peptid-Derivate.
CA2093202A1 (en) Sterilant gas mixture
CA2324217A1 (en) Process for the synthesis of hiv protease inhibitors
CA2109433A1 (en) Substituted benzhydrylamines as handles for solid phase peptide synthesis
AU671783B2 (en) Cathepsin-L-specific inhibitor polypeptide
NZ506667A (en) A process for the conversion of echinocandin class of peptides to their c4-homotyrosine monodeoxy analogues
SE9800865D0 (sv) New Process
WO2004029081A3 (en) Modified glp-1 peptides with increased biological potency
NZ508812A (en) Peptides for the prevention or treatment of HIV
ES2167464T3 (es) Procedimiento para la preparacion de n-carboxianhidridos de aminoacidos a partir de n-(n'-nitrosocarbamoil)aminoacidos.
EP1213297A4 (en) NOVEL TACHYKININ PEPTIDES, THEIR PRECURSOR PEPTIDES AND GENES ENCODING THEM
GB8723485D0 (en) Solution synthesis of octapeptide
MX9710225A (es) Inhibidores calpaina para el tratamiento de enfermedades neurodegenerativas.
WO2003029290A1 (en) Drug transporter and use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050711

AC Divisional application: reference to earlier application

Ref document number: 1289968

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY CZ DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IMMUPHARMA (FRANCE) SA

Owner name: THE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY CZ DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

17Q First examination report despatched

Effective date: 20070522

AKX Designation fees paid

Designated state(s): AT BE CH CY CZ DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071204